AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
Last trade$2.12
Day change+$0.03 (+1.44%)
Day range$2.04 – $2.12
Volume101,263
Market cap$208M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for ACIU.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for ACIU.
Recent news
Company coverage with links to the original publishers.
Summit Therapeutics received an FDA Complete Response Letter (CRL) for ivonescimab plus chemotherapy in NSCLC patients, declining approval due to insufficient evidence of effectiveness. While the HARMONi trial met its progression-free survival endpoint, it failed to demonstrate statistically significant overall survival benefit. The decision represents a major regulatory setback, delaying the company's first marketed product and U.S. commercial revenues.
Kodiak Sciences reported a Q3 2026 loss of $1.05 per share, wider than expected, as R&D expenses rose 15.5% year-over-year. However, the company announced positive phase III DAYBREAK study results for lead candidate Zenkuda and KSI-501, both meeting primary endpoints against Regeneron's Eylea. Kodiak plans to submit a BLA for Zenkuda by year-end and expects KSI-101 data in December 2026.
Altimmune reported a Q3 2026 loss of 15 cents per share, missing consensus estimates by one cent. R&D expenses surged 80.6% to $27 million due to ongoing pemvidutide clinical studies. The company has $480 million in cash expected to fund operations into 2029. Stock declined 17% following the announcement due to concerns over rising development costs and funding uncertainty for the planned phase III AUD program.
Aura Biosciences completed enrollment and dosing in its phase III CoMpass study evaluating bel-sar for early choroidal melanoma treatment. Top-line data is expected in the second half of 2027. If successful, bel-sar could become the first FDA-approved frontline vision-preserving therapy for this indication. The company is also exploring bel-sar for choroidal metastases and ocular surface cancers, with updates expected in Q1 2027. AURA shares have risen 39.6% year-to-date.
Zoetis announced USDA approval for Cytopoint Plus, a monoclonal antibody therapy providing 75 days of relief from allergic itch in dogs. The extended dosing interval is approximately 1.5 times longer than existing mAb options, expanding Zoetis' canine dermatology portfolio alongside Cytopoint, Apoquel, and Apoquel Chewable. Market uptake will depend on pricing, veterinary recommendations, and real-world performance.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.